Clinical, economic, and patient-reported impact of obesity in the Asia-Pacific region: A Systematic Review



Scan or click the QR code for a list of all Lilly content presented at the congress. Other company and product names are trademarks of their respective owners.

Esther Artime¹, Matilde Franceschini², Sam Riley², Julie Mount³, Arash Tahbaz³, Caragh Flannery⁴ Rachel S Newson⁵

¹Eli Lilly and Company, Alcobendas, Madrid, Spain; ²Adelphi Values, Adelphi Mill, Bollington, Cheshire, UK; ³Eli Lilly and Company Ltd, UK; ⁴Eli Lilly Cork Ltd – Global Business Solutions Centre, Cork, Ireland; ⁵Eli Lilly and Company, Sydney, Australia

Sponsored by Eli Lilly and Company

BACKGROUND

- While the epidemic of obesity is well documented in Western countries, less is known about the extent of the problem in the Asia-Pacific APAC region.¹
- Obesity is a disease that contributes to several diseases (adiposity related complications), including diabetes type 2, cardiovascular diseases, and psychological problems, such as depression, stress, and anxiety.^{2,3}
- As the impact of obesity is influenced by numerous factors such as access to treatment, societal and patient perceptions, and differences in cultural attitudes⁴, a comprehensive understanding of the existing epidemiological, clinical, patient-reported, and economic evidence is warranted.

STUDY DESIGN

Following PRISMA guidelines, a multi-region systematic literature review

OBJECTIVE

A systematic review of real-world evidence regarding the clinical, economic and patient-reported outcomes of obesity in the Asia-Pacific (APAC).


CONCLUSION

- Results indicate obesity is prevalent in the APAC region with notable presence of weight-related metabolic, cardiovascular, and psychological comorbidities.
- Obesity notably impacted the psychosocial sphere, physical functioning, and HRQoL of PwO, leading to the elevated use of health resources.
- This review helped identify key data gaps (e.g., limited data on HRQoL impact which was only available for Australia).

ISPOR Europe; Copenhagen, Denmark; 12-15 November 2023


Disclosures: EA, JM, AT, CF, and RSN are employees and minor stake/shareholders of Eli Lilly and Company. MF and SR are employees of Adelphi Values. Adelphi Values received consultancy fees for conduct of the research.


Figure 1. PRISMA Flow Diagram



(SLR) was performed in selected European and APAC countries, and Canada for the period 2018 to 2023. Here we report results for the APAC region (i.e., Japan, Australia, Korea, China, Taiwan, and Hong Kong).

- Medline and Embase database searches were conducted in December 2022, with grey literature (local and international congresses and online supplementary) searches conducted in May 2023 to identify real-world multi-country and country-specific studies reporting the burden of obesity in adults, published in English or local language.
- We present here initial results from the searches; final numbers may be subject to minor updates.







*Reasons for exclusion at screening include geographical location, study type, study population, intervention and outcomes.

KEY RESULTS

WHO, world health organization.



Economic impact of obesity in the APAC Region



*Note: ±, with or without diabetes; JPY, Japanese Yen; KRW, South Korea Won; OOPE, out-of-pocket expenses; SD, standard deviation.

Copyright ©2023 Eli Lilly and Company. All rights reserved.

*Psychological distress using K10 scores: low (10–15), moderate (16–21), high (22–29), very high (30–50). ** HRQoL was only available for Australia. ***HRQoL SF36: better health status is signified by higher scores.

ReferencesReferences¹World Health Organization. WHO European regional obesity report 2022. doi: 9789289057738-eng.pdf; ²Tremmel M, et al. Economic Burden of Obesity: A Systematic Literature Review. International journal of environ; ³Hecker, et al. Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. BMC Public Health 22, 46 (2022); ⁴Mauro et al (2007) Barriers to obesity treatment European Journal of Internal Medicine 2008 Vol. 19 Issue 3 Pages 173-180. **References for included systematic review publications on request**